Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Ранг среди акций #36447
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Цена акции
$1.73
Последняя синхронизация: 2025-06-17
Рыночная капитализация
$2.55M
Изменение (1 день)
-0.29%
Изменение (1 год)
-79.71%
Страна
US
Торговля Eiger BioPharmaceuticals, Inc. (EIGR)

Категория

Healthcare
EPS для Eiger BioPharmaceuticals, Inc. (EIGR)
EPS по состоянию на December 2023 TTM: $-50.79
Согласно последним финансовым отчетам и цене акций Eiger BioPharmaceuticals, Inc., текущий EPS компании (TTM) составляет $-50.79. В конце 2022 EPS компании составлял $-69.74, больше, чем показателю 2021 года, равному $-29.98.
История EPS компании Eiger BioPharmaceuticals, Inc. с 2016 по 2026
EPS на конец каждого года
Год EPS Изменить
2026 (TTM) $-50.79 0.02%
2023 $-50.78 -27.19%
2022 $-69.74 132.62%
2021 $-29.98 -56.76%
2020 $-69.34 -25.04%
2019 $-92.50 -19.31%
2018 $-114.63 -21.43%
2017 $-145.90 -37.96%
2016 $-235.16 0.00%
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -134.10%
US
$-7.98 -84.29%
US
$-5.29 -89.58%
AU
- -
CH
$27.74 -154.62%
NL